New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win
4 Articles
4 Articles
New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win
(MedPage Today) -- Oral ralinepag is positioned for potential FDA approval following its strong results as a treatment for pulmonary arterial hypertension (PAH) in an international phase III trial. In ADVANCE OUTCOMES, ralinepag conferred a reduction...
The National Agency for Health Surveillance (Anvisa) has granted registration for a new medicine for the treatment of adult patients with pulmonary hypertension associated with interstitial pulmonary disease (HP-DPI). Approval represents a significant milestone for a group of patients who, until then, did not have specific therapeutic options registered in Brazil for this condition. The [...]
Tyvaso is indicated for patients with pulmonary hypertension associated with interstitial lung disease and still depends on the price definition to reach the market
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
